Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2026PharmaceuticalsOpen Access

Glimepiride plus bisoprolol reduces HbA1c ~53% versus untreated controls in diabetic rats.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does co-administration of bisoprolol or amlodipine with glimepiride modify glycemic control in a diabetic rat model?

Population

100 adult male Wistar rats. T2DM induced with high-fat diet plus low-dose streptozotocin and confirmed by…

Comparison

Glimepiride + bisoprolol or glimepiride +… vs Healthy and diabetic untreated controls…

Design

Preclinical, allocated to ten parallel groups

Follow-up

11 weeks

Key result

Glimepiride plus bisoprolol achieved near-normal week-11 HbA1c (4.37%) compared to untreated diabetic controls (9.31%), enhancing glimepiride-mediated glycemic control in a diabetic rat model.

Authors

MHMohammad HailatZHZeyad HailatMIMo’ath Ifraitekh

Discussion

Loading...

Member takes

Overview

Antihypertensive effects on sulfonylurea glycemic control in T2DM remain unclear; animal data leave open need for clinical trials.

Key Points

  • This research investigates the effects of bisoprolol and amlodipine on glycemic control when co-administered with glimepiride in a diabetic rat model.
  • One hundred Wistar rats allocated to ten groups, examining effects of glimepiride with bisoprolol or amlodipine and respective monotherapies.
  • T2DM induced using a high-fat diet and low-dose streptozotocin, with glucose and HbA1c monitored for 11 weeks.
  • Statistical analyses included non-parametric methods and machine learning techniques like Random Forest regression.
  • Glimepiride + bisoprolol group achieved HbA1c of 4.37% ± 0.15, similar to healthy controls (p ≥ 0.33).
  • Amlodipine did not significantly reduce HbA1c, remaining high at 8.47% ± 0.20, near untreated controls (9.31% ± 0.18).
  • Random Forest prediction accuracy was high (R2 = 0.985), aligning with statistical findings on treatment effectiveness.

Structured PICO

Does co-administration of bisoprolol or amlodipine with glimepiride modify glycemic control in a diabetic rat model?

P
Population
100 adult male Wistar rats with induced T2DM, allocated to 10 parallel groups to evaluate glycemic control over 11 weeks.
I
Intervention
Glimepiride + bisoprolol or glimepiride + amlodipine
C
Comparator
Healthy and diabetic untreated controls; glimepiride, bisoprolol, or amlodipine monotherapy
O
Outcome
Glycated hemoglobin (HbA1c) at 11 weekssurrogate

Main Result

Absolute Event Rate: 4.37% vs 9.31%

p-value: p=<0.001

In a diabetic rat model, co-administration of bisoprolol enhanced glimepiride-mediated glycemic control, suggesting cardioselective beta-blockade may be a metabolically favorable antihypertensive partner for sulfonylurea therapy.

Limitations

  • Preclinical model warranting clinical confirmation

Cite This Study

Hailat et al. (2026) studied Diabetes mellitus type 2 (T2DM) (n=100). Glimepiride + bisoprolol vs. Untreated diabetic controls was evaluated on Week-11 HbA1c (p=<0.001). Glimepiride plus bisoprolol achieved near-normal week-11 HbA1c (4.37%) compared to untreated diabetic controls (9.31%), enhancing glimepiride-mediated glycemic control in a diabetic rat model.

synapsesocial.com/papers/6a5330a44f7abc118aded4d7https://doi.org/10.3390/ph19071064
View Full Paper
Ask AI
Bookmark
Share